The persistent mislabeling of penicillin allergies creates a cascade of clinical problems that extend far beyond individual patient care. When healthcare systems assume every reported penicillin allergy is legitimate, they force clinicians toward broader-spectrum antibiotics that fuel resistance patterns and compromise treatment outcomes across entire patient populations.
Belgian researchers deployed a systematic screening questionnaire across three regional hospitals to identify patients whose penicillin allergy labels could be safely removed. Among 8,659 patients evaluated during preoperative consultations, 600 reported penicillin allergies. The intervention successfully delabeled 124 patients—representing one in five cases—through either direct questionnaire assessment or follow-up file analysis and testing. The screening tool categorized patients into risk tiers, enabling immediate delabeling for those reporting vague childhood reactions or non-allergic side effects.
This pragmatic approach addresses a well-documented clinical reality: over 90% of reported penicillin allergies prove unfounded upon rigorous evaluation. The Belgian model demonstrates that structured delabeling can be integrated into routine preoperative workflows without requiring specialized allergy testing infrastructure. However, the 6.9% prevalence of reported penicillin allergy in this cohort appears lower than typical population estimates of 8-15%, potentially reflecting regional prescribing patterns or patient demographics. The intervention's success rate of 20% delabeling suggests significant room for expanding such programs, particularly given that many patients avoid evaluation due to persistent fear of severe reactions that likely never existed.